Search

everythinglearnresearchcommunity

for

Search:↓

Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

The user is pleased with their hair transplant results but is concerned about the vertex area. They use Minoxidil and finasteride daily and had the procedure at a clinic in Athens.

Dutasteride and finasteride are not effectively stopping hair loss for some users, despite long-term use. Some are considering or using RU58841, pyrilutamide, and other treatments like microneedling, while also managing seborrheic dermatitis with diet and topical solutions.

Dutasteride raises scalp testosterone by 99%, which may not be ideal for those sensitive to all androgens. Some argue finasteride's balancing act might be better, while others believe dutasteride is superior for hair regrowth.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

The user is using dutasteride 0.5mg every other day and recently started minoxidil 5% with a dermaroller. Initial side effects included watery semen, erection difficulties, and chest pain, but these have resolved.

OP used oral Dutasteride and Minoxidil but saw significant improvement only after adding PRP treatments. PRP sessions every 4 months maintained the results, though it is expensive.

Hair loss discussion includes fluridil (eucapil) and alfatradiol. Users share improvement experiences and alternative treatments in comments.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The conversation is about the effectiveness of Dutasteride (DUT) for hair loss. Some users have had positive results with DUT, while others have experienced negative effects. Different opinions and experiences are shared, including the mention of Ashton Kutcher using DUT for 20 years without problems.

A user shared their experience with scalp micropigmentation (SMP) after one year. They discussed using Minoxidil, finasteride, and RU58841 as treatments for hair loss.

Using a combination of low-dose topical finasteride (0.025%) and 0.5% pyrilutamide for hair loss, with a focus on minimizing side effects. The user seeks experiences and results from others who have tried this combination.

The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The results of using Dutasteride to treat hair loss after one month, and whether these results could be from longer hair alone.

The user tried Finasteride, Dutasteride, Minoxidil, RU58841, dermarolling, and oral castor oil for hair loss. They found RU58841 and Minoxidil most effective with no side effects, while Finasteride and Dutasteride caused sexual side effects.

User had success with dutasteride for hair loss after finasteride didn't work. Some experienced increased cholesterol and debated its relation to DHT.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

OP wants to increase pyrilutamide concentration from 0.5% to 1% while already using finasteride. Users suggest waiting for a commercial 1% solution and caution against using grey market products.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

A 25-year-old shared progress pictures after using finasteride 1mg daily for 6 months and dutasteride 1.5mg daily for another 6 months, noting significant hair regrowth, especially in the temporal peaks, with no side effects. The user switched from finasteride to dutasteride for more effective treatment.

A user is seeking recommendations for dermatologists or hair clinics in the Greater Sacramento or Bay Area for exosome treatments, comparing topical application plus microneedling versus direct scalp injections. They are also asking for personal experiences and before-and-after photos.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Users inquire about experiences with Pyrilutamide Kx group buys.

Clascoterone is considered overhyped and not as effective as finasteride or dutasteride, but it may be useful as a supportive treatment in combination with other therapies. Users express skepticism about its effectiveness compared to clinical trials, with some suggesting it could be beneficial for those who cannot tolerate other treatments.

A 35-year-old shared a 7-day update on their hair transplant, which involved 3,153 grafts performed by Dr. Elif at HLC Ankara, costing 10,000 euros including accommodations. The user has been on finasteride for over 12 years and opted for a partial shave FUE to address hairline recession and temple peaks.

The user switched from Finasteride to topical Dutasteride, Pyrilutamide, and Minoxidil due to hair loss, then decided to switch to oral Dutasteride because of pregnancy concerns. They are considering the frequency of oral Dutasteride use, with suggestions of using it a few times a week for better results and fewer side effects.

A 22-year-old switched from finasteride to dutasteride for hair loss treatment, also using RU58841, and is managing hypothyroidism. Despite ongoing shedding, they report some improvement and plan to continue dutasteride for a year before considering minoxidil.

A 21-year-old MTF individual is experiencing rapid hair thinning and is currently on estradiol valerate. They are inquiring about the effectiveness of spironolactone for hair loss, despite being aware of its serious side effects.